To Engineer Recovery, Sinobiomed’s New American Leaders Seek Licensing Deals, Strategic Investment From Global Pharma
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Aiming to reverse a 97.5 percent decline in the company's valuation over the past two years, the board of directors of Sinobiomed has appointed a team of American executives charged with engineering a recovery